Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Alexion's 5G1.1 completes phase I pilot study

Jan. 10, 2002

Life Medical Sciences given green light for trial of Repel-CV in neonatal patients

Jan. 9, 2002

Chugai researchers design vitamin D3 analogues with antipsoriatic activity

Jan. 4, 2002

Pharmacia granted rights to foam delivery technology for use with Rogaine

Jan. 4, 2002

GSK discontinues development of ADL-2-1294

Dec. 27, 2001

SkyePharma withdraws Solaraze termination notice

Dec. 27, 2001

Tetracyclic CXCR1/CXCR2 receptor antagonists in development at Pfizer

Dec. 18, 2001

U.S. clearance for Elidel Cream 1% for mild to moderate eczema

Dec. 18, 2001

Enrollment ahead of schedule in ISAtx-247 phase II psoriasis trial

Dec. 17, 2001

SkyePharma and Astralis sign agreements for Psoraxine

Dec. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...